Kesimpta
Kesimpta ingredients
| Active ingredient | Strength |
|---|---|
| Ofatumumab | 20 mg/.4mL |
What Kesimpta is used for
The FDA lists the approved uses on the official label (below). In the EU, ofatumumab is approved as Kesimpta for:
Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features (see section 5.1).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Kesimpta
- Generic name
- Ofatumumab
- Made by
- Novartis Pharmaceuticals Corporation
- Forms
- Injection, Solution
- Given
- Subcutaneous
- Drug class
- CD20-directed Cytolytic Antibody
- FDA approval
- Biologic licence (BLA) BLA125326
- On the US market since
- 2009
Official information
- Kesimpta prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Ofatumumab)
In India
- Ofatumumab: 2 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Kesimpta?
Kesimpta (Ofatumumab) is a cancer medicine made by Novartis Pharmaceuticals Corporation, approved by the US FDA.
What are the ingredients of Kesimpta?
Kesimpta contains Ofatumumab (20 mg/.4mL).
Is Kesimpta approved in Europe?
The same active substance is approved in the EU as Kesimpta.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA